Sainuo Biology Completes Pre-A Financing Round, Led by BGI Co-win

According to PEdaily.cn, Nanjing Sainuo Biology ("Sainuo Biology") has announced the completion of its Pre-A financing, led by BGI Co-win with participation from the existing investor in the angel round, Dynamic Balance Capital. Proceeds of this financing will mainly be used for the clinical application of Sainuo Biology's SN001 project, the establishment of a pilot plant in line with GMP standards, as well as the screening of new biological drugs for diabetes and CMC research.

Sainuo Biology was founded by a group of veterans who have many years of development experience in the field of biological drugs. The technical team of Sainuo Biology has rich experience from project approval, pre-clinical researches, clinical trials, production to registration. The company aims to develop more high-end biological drugs for diabetics, including GLP-1 treatments and insulin treatments based on genetic engineering, and other innovative biologics and therapies.

For diabetes treatment, Sainuo Biology has developed two new drugs, namely SN001 and SN004. SN001 is a novel hypoglycemic drug in the pre-clinical research stage, which still has a long patent period. This drug can effectively reduce fasting blood glucose and the incidence of nocturnal hypoglycemia, and shows a more stable PK/PD curve. 

SN004 is an upgraded version of SN001, independently screened and developed by Sainuo Biology and supported by foreign research and development laboratories. SN004 can achieve a longer action period and is currently in the confirmation of the pre-clinical research stage.

Founded in 2016, BGI Co-Win is the corporate venture capital arm of BGI Genomics and is based in Shenzhen, China. The firm seeks to invest in medical technology, gene technology and biomedical companies.

Dynamic Balance Investment is a core subsidiary of Jiangning Technology Venture Capital, The company focuses on investments in the biomedical, TMT, clean energy and new material industries.